Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2584 - Outcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: focus on a special patient population


10 Sep 2017


Poster display session


Urothelial Cancers


Andrea Necchi


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


A. Necchi1, G.R. Pond2, S.K. Pal3, N. Agarwal4, D. Bowles5, E.R. Plimack6, E.Y. Yu7, S. Ladoire8, J. Baniel9, S. Crabb10, G. Niegisch11, A.R. Golshayan12, S. Sridhar13, D. Berthold14, J.E. Rosenberg15, T. Powles16, A. Bamias17, L.C. Harshman18, J. Bellmunt19, M.D. Galsky20

Author affiliations

  • 1 Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Biostatistics, McMaster University, Hamilton/CA
  • 3 Medicine, City of Hope, 91010 - Duarte/US
  • 4 Medical Oncology, Huntsman Cancer Institute, 84112 - Salt Lake City/US
  • 5 Medical Oncology, University of Colorado Denver, 80045 - South Aurora/US
  • 6 Medical Oncology, Fox Chase Cancer Center, 19111-2497 - Philadelphia/US
  • 7 Medicine, University of Washington, Seattle/US
  • 8 Medical Oncology, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 9 Medical Oncology, Rabin Medical Center, Petach Tikva/IL
  • 10 Medical Oncology, Southampton General Hospital Southampton University Hospitals NHS Trust, SO16 6YD - Southampton/GB
  • 11 Urology, Heinrich-Heine-University Düsseldorf, 40225 - Düsseldorf/DE
  • 12 Medical Oncology, Medical University of South Carolina, Charleston/US
  • 13 Medical Oncology, Princess Margaret Hospital, M5G 2M9 - Toronto/CA
  • 14 Medical Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 15 Genitourinary Oncology Section, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 16 Oncology, St. Bartholomew's Hospital, EC1A 7BE - London/GB
  • 17 Therapeutics Oncology, National and Kapodistrian University of Athens, Athens/GR
  • 18 Medical Oncology, Dana-Farber Cancer Institute, 2215 - Boston/US
  • 19 Genitourinary Oncology, Dana-Farber Cancer Institute , Boston, MA/US
  • 20 Medical Oncology, Icahn School of Medicine at Mount Sinai, New York/US


Abstract 2584


Patients (pts) with aUC with exclusive bone metastatic spread represent a rare subgroup of pts with unique clinical features. These pts deserve special consideration, as they are usually excluded from clinical trials due to the lack of measurable disease according to RECIST criteria. We focused on their access to treatment and outcomes in a retrospective study.


Cases were extracted from the pool of 1,911 pts with a diagnosis of mUC from the RISC database (db). Data from 23 centers was collected. Results of 1st-line, platinum-based chemotherapy in bone-only pts were compared with those from the remaining pts in the RISC db. Summary statistics were used to describe pt characteristics and outcomes. Kaplan-Meier method was used to estimate time to event outcomes such as progression-free survival (PFS) and overall survival (OS). Both OS and PFS are measured from the date of diagnosis of metastatic disease. Univariable and multivariable Cox analyses were performed. All tests were two-sided and statistical significance was defined as a p-value ≤0.05.


A total of 128 evaluable pts (6.7%), treated between 02/1997 and 04/2013, were identified. ECOG-PS was ≥1 in 85.9% vs. 66.3% of the remaining pts from RISC db. 73 (57%) received 1st-line chemotherapy, that was platinum-based in all pts, and 28 of them (38.4%) 2nd-line CT (vs. 75.8% and 42.5%, respectively, from the RISC db). On multivariable analyses, only the chemotherapy administration was significantly associated with improved OS among bone-only mUC pts (p 


Pts with bone only metastases are less likely to receive systemic therapy than pts with metastases to other sites, likely due to lower PS. The prognostic impact of having exclusive bone metastases or additional sites seems to be equally poor. Clinical trials with new agents should focus on this population.

Clinical trial identification

Legal entity responsible for the study

Andrea Necchi




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.